Cytoprotection of pancreatic islets before and early after transplantation using gene therapy.
Pancreatic islet transplantation (PIT) is an attractive alternative to insulin-dependent diabetes treatment but is not yet a clinical reality. The first few days after PIT are characterized by substantial pancreatic islet dysfunction and death. Apoptosis has been documented in PI after extracellular matrix removal, during culture time, after exposure to proinflammatory cytokines, hypoxic conditions before islet revascularization, and rejection. Targeting the apoptosis pathway by adenoviral-mediated gene transfer of the anti-apoptotic Bcl-2 gene exerts a major cytoprotective effect on isolated macaque pancreatic islets. Bcl-2 transfection ex vivo protects islets from apoptosis induced by disruption of the islet extracellular matrix during pancreatic digestion. Additionally, over-expression of Bcl-2 confers long-term, stable protection and maintenance of functional islet mass after transplantation into diabetic SCID mice. Genetic modification of PI also reduced the islet mass required to achieve stable euglycemia. Ex vivo gene transfer of anti-apoptotic genes has potential as a therapeutic approach to both minimize loss of functional islet mass post-transplant and reduce the high islet requirement currently needed for successful stable reversal of insulin-dependent diabetes [1, 2].
Contreras
Juan L
JL
Transplant Center and Division of Human Gene Therapy, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Bilbao
Guadalupe
G
Smyth
Cheryl A
CA
Eckhoff
Devin E
DE
Jiang
Xiao L
XL
Jenkins
Stacie
S
Thomas
Francis T
FT
Curiel
David T
DT
Thomas
Judith M
JM
D000818:Animals; D019610:Cytoprotection; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D007515:Islets of Langerhans / Q000166:cytology*; D016381:Islets of Langerhans Transplantation; D008253:Macaca mulatta; D008297:Male; D011182:Postoperative Care; D011300:Preoperative Care; D013997:Time Factors